Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
- Conditions
- Alveolar RhabdomyosarcomaBotryoid-Type Embryonal RhabdomyosarcomaEmbryonal RhabdomyosarcomaSclerosing RhabdomyosarcomaRhabdomyosarcomaSpindle Cell Rhabdomyosarcoma
- Interventions
- Drug: CyclophosphamideBiological: DactinomycinDrug: Irinotecan HydrochlorideOther: Laboratory Biomarker AnalysisOther: Questionnaire AdministrationRadiation: Radiation TherapyDrug: Vincristine SulfateDrug: TemsirolimusDrug: Vinorelbine
- First Posted Date
- 2015-10-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 325
- Registration Number
- NCT02567435
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸Atrium Health Navicent, Macon, Georgia, United States
🇺🇸Springfield Memorial Hospital, Springfield, Illinois, United States
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)
- Conditions
- Esophageal CarcinomaEsophagogastric Junction Carcinoma
- Interventions
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 628
- Registration Number
- NCT02564263
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
- Conditions
- Pancreatic AdenocarcinomaResectable Pancreatic Carcinoma
- Interventions
- First Posted Date
- 2015-09-29
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 147
- Registration Number
- NCT02562716
- Locations
- 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Licking Memorial Hospital, Newark, Ohio, United States
🇺🇸Geisinger Medical Group, State College, Pennsylvania, United States
Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 64
- Registration Number
- NCT02558959
- Locations
- 🇨🇳
First affiliated hospital, Zhejiang University, Hangzhou, Zhejiang, China
Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2018-06-21
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 80
- Registration Number
- NCT02558868
- Locations
- 🇨🇳
First affiliated hospital, Zhejiang University, Hangzhou, Zhejiang, China
A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma
- Conditions
- Pancreatic CancerCarcinoma
- Interventions
- Drug: GemcitabineDrug: Folinic AcidDrug: 5-Fluoro-uracilDrug: OxaliplatinDrug: IrinotecanDrug: L-folinic
- First Posted Date
- 2015-09-03
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 171
- Registration Number
- NCT02539537
- Locations
- 🇫🇷
Hôpital Trousseau, Chambray-les-tours, France
🇫🇷Hôpital Avicenne, Bobigny, France
🇫🇷CHU Amiens - Hôpital Nord, Amiens, France
A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab
- Conditions
- Colorectal Cancer
- Interventions
- Drug: fluorouracilDrug: LeucovorinDrug: irinotecanDrug: oxaliplatinBiological: bevacizumabBiological: cetuximab
- First Posted Date
- 2015-08-05
- Last Posted Date
- 2015-08-05
- Lead Sponsor
- Japan Clinical Cancer Research Organization
- Target Recruit Count
- 360
- Registration Number
- NCT02515734
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
- Conditions
- Ewing's Sarcoma
- Interventions
- First Posted Date
- 2015-07-29
- Last Posted Date
- 2022-12-22
- Lead Sponsor
- Gradalis, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT02511132
- Locations
- 🇺🇸
Mary Crowley Cancer Research Centers, Dallas, Texas, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Nicklaus Children's Hospital (Miami Children's Health System), Miami, Florida, United States
FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
- Conditions
- Recurrent Colorectal CarcinomaStage IVA Colorectal CancerStage IVB Colorectal Cancer
- Interventions
- Drug: FluorouracilDrug: Irinotecan HydrochlorideOther: Laboratory Biomarker AnalysisDrug: Leucovorin CalciumBiological: Panitumumab
- First Posted Date
- 2015-07-24
- Last Posted Date
- 2018-08-16
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 1
- Registration Number
- NCT02508077
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸City of Hope Antelope Valley, Lancaster, California, United States
🇺🇸City of Hope Rancho Cucamonga, Rancho Cucamonga, California, United States
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
- Conditions
- Carcinoma, Non-Small-Cell LungNeuroendocrine TumorsSmall Cell CarcinomaOvarian Epithelial Cancer
- Interventions
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2022-10-03
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 139
- Registration Number
- NCT02489903
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸Baptist Health, Lexington, Kentucky, United States
🇺🇸Memorial Hospital of South Bend, South Bend, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.